Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOS789 in CKD Patients with Hyperphosphatemia on Hemodialysis
NCT02965053Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EOS789 in hyperphosphatemia (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Incidences of adverse events, Change from baseline in vital signs and 2 more. Started Dec 2016; status: completed.
02
Drugs
EOS789
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT02965053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965053.